Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Kohei Shitara(National Cancer Center Hospital East), Kei Muro(Aichi Cancer Center), Yasuhiro Shimada(Tokyo National Hospital), Shuichi Hironaka(Chiba Cancer Center), Naotoshi Sugimoto(Osaka Medical Center for Cancer and Cardiovascular Diseases), Yoshito Komatsu(Hokkaido University Hospital), Tomohiro Nishina(Shikoku Cancer Center), Kensei Yamaguchi(Saitama Cancer Center), Yoshihiko Segawa(Saitama Medical University), Yasushi Omuro(Tokyo Metropolitan Komagome Hospital), Takao Tamura(Kindai University), Toshihiko Doi(National Cancer Center Hospital East), Seigo Yukisawa(Tochigi Cancer Center), Hirofumi Yasui(Shizuoka Cancer Center), Fumio Nagashima(Kyorin University Hospital), Masahiro Gotoh(Osaka Medical and Pharmaceutical University), Taito Esaki(National Hospital Organization Kyushu Cancer Center), Michael Emig(Eli Lilly (Germany)), Kumari Chandrawansa(Eli Lilly (United States)), Astra M. Liepa(Eli Lilly (United States)), H. Wilke(Kliniken Essen-Mitte), Yukako Ichimiya(Eli Lilly (Japan)), Atsushi Ohtsu
Cited by 86Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis